tifacogin profile

Tifacogin: a recombinant form of tissue factor pathway inhibitor, RN & amino acid sequence in first source; MW about 32 kDa [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	961320
SCHEMBL ID	3625005
MeSH ID	M0352035

Synonym
148883-56-1
AKOS000226216
1-phenyl-n-(thiophen-2-ylmethyl)methanamine
STK510839
SCHEMBL3625005
tifacogin
benzyl(thiophen-2-ylmethyl)amine
FT-0643425
n-benzyl-1-(thiophen-2-yl)methanamine
73325-61-8
2-thienyl n-benzyl methyl amine
mfcd01764729
benzyl-thiophen-2-ylmethyl-amine
benzylthiophen-2-ylmethylamine
blood-coagulationfactor laci(human clone lp9 protein moiety reduced),n-l-alanyl-
1-phenyl-n-[(thiophen-2-yl)methyl]methanamine
DTXSID70933497
(2r)-(-)-glycidyl4-nitrobenzoate
1-phenyl-n-(2-thienylmethyl)methanamine
YFA88356
CS-0213282
benzyl[(thiophen-2-yl)methyl]amine

Excerpt	Reference	Relevance
"Treatment with tifacogin had no effect on all-cause mortality in patients with severe sepsis and high INR. "	( Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. Abraham, E; Artigas, A; Beale, R; Creasey, AA; De Deyne, C; Demeyer, I; Doig, C; Laterre, PF; Light, B; Opal, S; Peckelsen, C; Percell, SR; Pettilä, V; Poole, L; Postier, R; Reinhart, K; Rodriguez, AL; Seibert, A; Shu, V; Simon, S; Spapen, H; Sprung, CL; Stolzenbach, JC; Stone, J; Svoboda, P; Tobias, J; Zwingelstein, C, 2003)	0.98

Excerpt	Reference	Relevance
" There was an increase in serious adverse events with bleeding in the tifacogin group in both cohorts (6."	( Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. Abraham, E; Artigas, A; Beale, R; Creasey, AA; De Deyne, C; Demeyer, I; Doig, C; Laterre, PF; Light, B; Opal, S; Peckelsen, C; Percell, SR; Pettilä, V; Poole, L; Postier, R; Reinhart, K; Rodriguez, AL; Seibert, A; Shu, V; Simon, S; Spapen, H; Sprung, CL; Stolzenbach, JC; Stone, J; Svoboda, P; Tobias, J; Zwingelstein, C, 2003)	0.86

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	1 (7.69)	18.2507
2000's	8 (61.54)	29.6817
2010's	4 (30.77)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	3 (23.08%)	5.53%
Reviews	3 (23.08%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	7 (53.85%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
mustard gas Mustard Gas: Severe irritant and vesicant of skin, eyes, and lungs. It may cause blindness and lethal lung edema and was formerly used as a war gas. The substance has been proposed as a cytostatic and for treatment of psoriasis. It has been listed as a known carcinogen in the Fourth Annual Report on Carcinogens (NTP-85-002, 1985) (Merck, 11th ed).. bis(2-chloroethyl) sulfide : An ethyl sulfide that is diethyl sulfide in which a hydrogen from each of the terminal methyl groups is replaced by a chlorine. It is a powerful vesicant regulated under the Chemical Weapons Convention.	2.48	2	ethyl sulfide; organochlorine compound	alkylating agent; carcinogenic agent; vesicant
2-chloroethyl ethyl sulfide [no description available]	2.48	2
fibrin Fibrin: A protein derived from FIBRINOGEN in the presence of THROMBIN, which forms part of the blood clot.	2.08	1	peptide
thromboplastin Thromboplastin: Constituent composed of protein and phospholipid that is widely distributed in many tissues. It serves as a cofactor with factor VIIa to activate factor X in the extrinsic pathway of blood coagulation.	3.53	2

Condition	Relationship Strength	Studies	Trials
Airway Obstruction Any hindrance to the passage of air into and out of the lungs.	2.48	2	0
Acute Hypercapnic Respiratory Failure [description not available]	2.08	1	0
Respiratory Insufficiency Failure to adequately provide oxygen to cells of the body and to remove excess carbon dioxide from them. (Stedman, 25th ed)	2.08	1	0
Community Acquired Infection [description not available]	6.19	4	1
Bacterial Pneumonia [description not available]	4.28	2	0
Pneumonia, Bacterial Inflammation of the lung parenchyma that is caused by bacterial infections.	4.28	2	0
Experimental Lung Inflammation Inflammation of any part, segment or lobe, of the lung parenchyma.	3.85	2	1
Pneumonia Infection of the lung often accompanied by inflammation.	8.85	2	1
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	2.07	1	0
Inflammatory Response Syndrome, Systemic [description not available]	5.01	3	1
Systemic Inflammatory Response Syndrome A systemic inflammatory response to a variety of clinical insults, characterized by two or more of the following conditions: (1) fever	5.01	3	1
Blood Poisoning [description not available]	2.94	1	0
Arteriosclerosis, Coronary [description not available]	2.94	1	0
Coronary Artery Disease Pathological processes of CORONARY ARTERIES that may derive from a congenital abnormality, atherosclerotic, or non-atherosclerotic cause.	2.94	1	0
Sepsis Systemic inflammatory response syndrome with a proven or suspected infectious etiology. When sepsis is associated with organ dysfunction distant from the site of infection, it is called severe sepsis. When sepsis is accompanied by HYPOTENSION despite adequate fluid infusion, it is called SEPTIC SHOCK.	2.94	1	0
Endotoxin Shock [description not available]	2.03	1	0
Shock, Septic Sepsis associated with HYPOTENSION or hypoperfusion despite adequate fluid resuscitation. Perfusion abnormalities may include but are not limited to LACTIC ACIDOSIS; OLIGURIA; or acute alteration in mental status.	2.03	1	0
Blood Clot [description not available]	3.39	1	1
Thrombosis Formation and development of a thrombus or blood clot in the blood vessel.	3.39	1	1
Coronary Thrombosis Coagulation of blood in any of the CORONARY VESSELS. The presence of a blood clot (THROMBUS) often leads to MYOCARDIAL INFARCTION.	2.92	1	0
Acute Disease Disease having a short and relatively severe course.	2.92	1	0

tifacogin

Description

Cross-References

Synonyms (22)

Research Excerpts

Treatment

Toxicity

Research

Studies (13)

Market Indicators

Research Demand Index: 20.03

Study Types